A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients.
MV Mateos(Instituto de Investigación Biomédica de Salamanca), Jesús F. San Miguel(Clinica Universidad de Navarra), Juan José Lahuerta(Research Institute Hospital 12 de Octubre), Joan Bladé(Hospital Clínic de Barcelona), Joaquín Díaz Mediavilla(Fundación Pethema), Javier de la Rubia(Universitat de València), Adrían Alegre(Hospital Universitario de La Princesa), Joan Bargay(Hospital Son Llatzer), Jesús María Hernández‐Rivas(Universidad de Salamanca), Miguel‐Teodoro Hernández(Hospital Universitario de Canarias), María José Terol(Hospital Clínico Universitario de Valencia), J García Laraña(Hospital Universitario Ramón y Cajal), P Gómez Rivas(Fundación Pethema), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Luis Palomera(BioCruces Health research Institute), Josep‐María Ribera(Universitat Autònoma de Barcelona), D. Schenkein(Millennium Engineering and Integration (United States)), Dixie‐Lee Esseltine(Millennium Engineering and Integration (United States)), Marı́a Jesús Moro(Fundación Pethema), Felipe Prósper(Institute of Human Genetics), D. Carrera(Hospital de Sant Pau), Felipe de Arriba(Hospital General Universitario Morales Meseguer)
Cited by 39
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
|Cell|2020|2.3k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k